Chiral Organophosphorus Pharmaceuticals: Properties and Application

被引:17
作者
Kolodiazhna, Anastasy O. [1 ]
Kolodiazhnyi, Oleg I. [1 ]
机构
[1] Natl Acad Sci Ukraine, VP Kukhar Inst Bioorgan Chem & Petrochem, Kukharia Acad St 1, UA-02094 Kiev, Ukraine
来源
SYMMETRY-BASEL | 2023年 / 15卷 / 08期
关键词
chiral phosphorus compounds; prodrugs; natural pharmaceuticals synthetic phosphorus drugs; bisphosphonates; phosphonosulfonates; phosphonopeptides; troyan horse" antibiotics; chiral switches; SQUALENE SYNTHASE INHIBITORS; DIASTEREOSELECTIVE SYNTHESIS; PHOSPHORAMIDATE PRODRUGS; BIOLOGICAL EVALUATION; PHOSPHONATE PRODRUGS; PRACTICAL SYNTHESIS; ANTIVIRAL ACTIVITY; CYCLIC CIDOFOVIR; AGROCIN; 84; ANALOGS;
D O I
10.3390/sym15081550
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
This review considers the chiral phosphorus-containing drugs used to treat patients in the clinic, as well as the promising and experimental drugs that are in the process of being researched. Natural and synthetic representatives of phosphorus-containing drugs, such as tenofovir (hepatitis B and HIV treatment), fosfomycin (antibiotic), valinofos (antibiotic), phosphazinomycin A (antibiotic), (R)-phospholeucine, various antibacterial and antifungal agents, renin inhibitors, etc., have found practical applications as medicines and bioregulators and other medicines. The influence of the chirality of both carbon atoms and phosphorus atoms on the pharmacodynamics, pharmacokinetics, and toxicological properties of phosphorus drugs has been demonstrated. Therefore, the choice of enantiomers is critical since the wrong choice of a chiral drug can lead to undesirable consequences, carcinogenicity, and teratogenicity. New chiral technologies affecting drug development are discussed, such as the "chiral switch" of racemates already on the market, as well as phosphorus-containing prodrugs with a higher biological selectivity and low adverse effects.
引用
收藏
页数:26
相关论文
共 125 条
  • [1] Agency E.M, 1994, INV CHIR ACT SUBST
  • [2] Putting chirality to work: The strategy of chiral switches
    Agranat, I
    Caner, H
    Caldwell, A
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2002, 1 (10) : 753 - 768
  • [3] [Anonymous], VIST CID DOS IND INT
  • [4] Inhibition of human immunodeficiency virus type 1 replication in acutely and chronically infected cells by EM2487, a novel substance produced by a Streptomyces species
    Baba, M
    Okamoto, M
    Takeuchi, H
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (10) : 2350 - 2355
  • [5] Substrate-Based Fragment Identification for the Development of Selective, Nonpeptidic Inhibitors of Striatal-Enriched Protein Tyrosine Phosphatase
    Baguley, Tyler D.
    Xu, Hai-Chao
    Chatterjee, Manavi
    Nairn, Angus C.
    Lombroso, Paul J.
    Ellman, Jonathan A.
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2013, 56 (19) : 7636 - 7650
  • [6] Cyclosaligenyl-2′,3′-didehydro-2′,3′-dideoxythymidine monophosphate:: Efficient intracellular delivery of d4TMP
    Balzarini, J
    Aquaro, S
    Knispel, T
    Rampazzo, C
    Bianchi, V
    Perno, CF
    De Clercq, E
    Meier, C
    [J]. MOLECULAR PHARMACOLOGY, 2000, 58 (05) : 928 - 935
  • [7] Microcins in Enterobacteriaceae: Peptide Antimicrobials in the Eco-Active Intestinal Chemosphere
    Baquero, Fernando
    Lanza, Val F.
    Baquero, Maria-Rosario
    del Campo, Rosa
    Bravo-Vazquez, Daniel A.
    [J]. FRONTIERS IN MICROBIOLOGY, 2019, 10
  • [8] Large-Scale Structural Analysis of the Classical Human Protein Tyrosine Phosphatome
    Barr, Alastair J.
    Ugochukwu, Emilie
    Lee, Wen Hwa
    King, Oliver N. F.
    Filippakopoulos, Panagis
    Alfano, Ivan
    Savitsky, Pavel
    Burgess-Brown, Nicola A.
    Mueller, Susanne
    Knapp, Stefan
    [J]. CELL, 2009, 136 (02) : 352 - 363
  • [9] METABOLITES OF MICROORGANISMS 98. PHOSPHINOTHRICIN AND PHOSPHINOTHRICYL-ALANYLALANINE
    BAYER, E
    ZAHNER, H
    KONIG, WA
    JESSIPOW, S
    GUGEL, KH
    HAGELE, K
    HAGENMAIER, H
    [J]. HELVETICA CHIMICA ACTA, 1972, 55 (01) : 224 - +
  • [10] Birnkrant D., 2021, BRINCIDOFOVIR NDA AP